Table 3.

Multivariable association between selected clinical variables and type of polypill equivalent, CoLaus study, Lausanne, Switzerland, 2009–2012 and 2014–2017.

	2009–2012		2014–2017
	Polypill equivalent A	Polypill equivalent B	Polypill equivalent A	Polypill equivalent B
Gender
Woman	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
Man	1.93 (1.45–2.55)	1.52 (1.17–1.96)	1.67 (1.27–2.19)	1.41 (1.07–1.85)
Age group
[40–50]	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
[50–60]	2.27 (1.26–4.08)	3.64 (1.97–6.74)	1.91 (0.79–4.62)	4.76 (1.46–15.50)
[60–70]	5.83 (3.37–10.06)	10.48 (5.87–18.72)	4.76 (2.03–11.17)	11.15 (3.49–35.64)
[70+]	11.71 (6.74–20.33)	13.22 (7.27–24.07)	9.56 (4.13–22.13)	20.63 (6.51–65.36)
p-value for trend	< 0.001	< 0.001	< 0.001	< 0.001
Smoking status
Never	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
Former	1.86 (1.35–2.55)	0.99 (0.74–1.31)	1.69 (1.24–2.31)	0.81 (0.60–1.08)
Current	1.60 (1.10–2.39)	0.98 (0.68–1.41)	2.11 (1.43–3.10)	0.89 (0.60–1.31)
p-value for trend	0.023	0.920	< 0.001	0.549
History of CVD
No	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
Yes	14.65 (10.21–21.02)	1.50 (0.92–2.46)	12.34 (9.23–16.50)	1.93 (1.33–2.78)

Results are expressed as odds ratio (95% confidence interval). Equivalent A: aspirin + statin + any antihypertensive; equivalent B: no aspirin + statin + any antihypertensive. Statistical analysis using logistic regression. Significant (p < 0.05) odds ratios are indicated in bold.